Tissue regeneration technology developer Orthocell’s CelGro Dental product has been recommended for inclusion on the Australian Prosthesis List, opening opportunities for Australian and international sales.
The list defines the benefit to be paid by private health insurers for the CelGro product.
The Perth company is commercialising products to facilitate the regeneration of severed peripheral nerves and bone, with its CelGro resorbable collagen device aimed at the dental bone and tissue regeneration market.
Managing director Paul Anderson said: “Inclusion on the prosthesis list is an important step in gaining reimbursement from private insurers.
“This is a significant milestone for our company.”
CelGro Dental, which recently received a new brand name, Striate+, was recommended by the Prosthesis List Advisory Committee.
This will now be considered by the Commonwealth health minister.
Subscribe to our free @AuManufacturing newsletter here.